A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg

NCT05698043 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

63

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension and Dyslipidemia

Interventions

DRUG: CKD-386(5)
DRUG: D013, D326, D337

Sponsor

Chong Kun Dang Pharmaceutical